A Comparison of Mirtazapine and Benzodiazepine in Patients with Acute Anxiety

Not Applicable

Conditions: Mental and behavioural disorders

Registration Number: KCT0007558

Lead Sponsor: Chung-Ang Univerisity Hospital

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot yet recruiting

Sex: All

Target Recruitment: 52

Inclusion Criteria

?the age between 18 and 65
?people diagnosed with major depressive disorder without psychotic features by the Structured Clinical Interview for DSM-5 (SCID-5)
?Beck Anxiety Inventory(BAI) scale score of 16 or higher (with moderate or severe anxiety symptoms)
?based on the baseline, those who have no history of taking Mirtazapine or Benzodiazepine in the last 2 months
?people who have been administered antidepressants(SSRI, SNRI, or NDRI) in stable doses for more than 1 month.

Exclusion Criteria

?people diagnosed with other psychiatric disorders by SCID-5-CV
?People with severe medical conditions (cancer, heart failure, renal failure, liver disease, lung disease, thyroid disease, and acute inflammatory conditions)
?people who have a history of substance dependence or misuse in the past or present
?people with a history of epilepsy, head injury, or organic mental disorder

Study & Design

Study Type: Interventional Study

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Beck Anxiety Inventory(BAI)

Secondary Outcome Measures

Name	Time	Method
Beck Depressive Inventory(BDI-II);Korean Symptom Check List 95 (KSCL95);Clinical Global Impression- Severity of illness (CGI-S) & Clinical Global Impression of Improvement (CGI-I);Quantitative Electroencephalogram(QEEG);functional Near-Infrared Spectroscopy(fNIRS)